

# Drug Utilization Review Board

## Meeting Minutes

Thursday, March 12, 2020  
7:15 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125

**Board Members Present:**

Jennifer Brinton, MD  
Judith Turner, DVM, PharmD  
Kumar Shah, MSc, PEng, Board Chair  
Kyle Kitchen, PharmD

Michelle Hoffman, MD  
Neal Catalano, PharmD  
Sharon Weinstein, MD  
Susan Siegfried, MD

**Board Members Excused:**

Katherine Smith, PharmD

Elizabeth Gargaro, MD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Mohit Bhakta, PharmD  
Jennifer Strohecker, PharmD  
Andrea Rico, CPhT, CPC

Ngan Huynh, PharmD  
Bryan Larson, PharmD  
Joe Busby, RPh, MBA

**University of Utah Drug Regimen Review Center Staff Presenter:**

Elena Martinez Alonso, B.S. Pharm, MSc MTSL, Medical Writer

**Other Individuals Present:**

Jennifer Lauper, BMS  
Yen Ma, U of U  
Jeff Sperry, U of U

Valerie Gonzales, U of U  
Matthew Call, U of U Health Plans

**Meeting conducted by: Mohit Bhakta**

---

1. **Welcome & Housekeeping:** Mohit Bhakta opened the meeting and reminded everyone to sign the rosters, and announced a quorum. Jennifer Strohecker discussed the preparation of the annual DUR Report will take place over the next couple of months. She also stated that the DOH is addressing access to care related to COVID 19.
2. **Review and Approval of February Minutes:** Kumar Shah made a motion to approve the minutes from February. Neal Catalano seconded the motion. All in favor, motion passed.
3. **P&T Committee Update:** Bryan Larson stated the topic for March P&T is Cystic Fibrosis Gene Therapies (elixacaftor/tezacaftor/ivacaftor, ivacaftor, lumacaftor/ivacaftor, and tezacaftor/ivacaftor). The meeting will be held remotely or postponed due to COVID 19.
4. **ADHD Medication Use in Adults:**

- a. **Information:** Elena Martinez presented peer-reviewed research regarding safety and efficacy, clinical trials, disease-state treatment guidelines for ADHD Medication Use in Children.
  - b. **Public Comment:** None
  - c. **Board Discussion:** The DURB reviewed the recommendations including requiring prior authorization for the use of stimulant agents in patients under the age of four, concurrent use of three or more stimulant combinations, the use of multiple short or long acting from different chemical entity, and setting quantity limits based upon the FDA recommended maximum daily dosages presented by Mohit Bhakta. Additional information can be found by listening to the recording located here <https://medicaid.utah.gov/pharmacy/drug-utilization-review-board/?p=DUR%20Board%20Audio%20Recordings/>
  - d. **Board Action:** Sharon Weinstein motioned to approve the recommendations as presented, Neal Catalano seconded the motion. All in favor, motion passed.
5. **Public Meeting Adjourned:** Neal Catalano motioned to close the meeting. Michelle Hoffman seconded the motion. Unanimous Approval.
  6. **The next meeting scheduled for** Thursday, April 09, 2020 Opioid Use Disorder Treatments in Pregnancy, Concurrent use of Opioid / MAT .

---

Audio recordings of DUR meetings are available online at:  
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board/?p=DUR%20Board%20Audio%20Recordings/>